UBS Lowered Firm’s PT on Elevance Health (ELV), Kept a Buy Rating

Elevance Health, Inc. (NYSE:ELV) is one of the Best 52-Week Low Stocks to Buy According to Analysts. On July 14, UBS analyst AJ Rice lowered the firm’s price target on Elevance Health, Inc. (NYSE:ELV) from $555 to $484, while keeping a Buy rating on the stock.

The cautious rating comes as the company gets close to releasing its Q2 2025 earnings. The analyst noted that Elevance Health, Inc. (NYSE:ELV) is the only managed care organization with government exposure showing meaningful positive EPS growth. However, he lowered the price target on the caution that the company might revise its earnings in the upcoming conference call.

UBS Lowered Firm's PT on Elevance Health (ELV), Kept a Buy Rating

A medical professional working at a computer, utilizing the company’s digital solutions to improve care quality for consumers.

During the fiscal first quarter of 2025, the company delivered revenue of $48.8 billion, up 15.4% year-over-year. Its adjusted operating gains also grew 4.1% to reach $3.3 billion. Management reaffirmed FY 2025 adjusted diluted EPS of $34.15 to $34.85 during the Q1 2025 earnings call.

Elevance Health, Inc. (NYSE:ELV) is a leading health insurer in the United States, providing a wide range of health plans and pharmacy services.

While we acknowledge the potential of ELV to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ELV and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.